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Gastric cancer is a global health burden and has the highest incidence in East Asia. This disease 
is complex in nature because it arises from multiple interactions of genetic, local environmental, 
and host factors, resulting in biological heterogeneity. This genetic intricacy converges on molec-
ular characteristics reflecting the pathophysiology, tumor biology, and clinical outcome. There-
fore, understanding the molecular characteristics at a genomic level is pivotal to improving the 
clinical care of patients with gastric cancer. A recent landmark study, The Cancer Genome Atlas 
(TCGA) project, showed the molecular landscape of gastric cancer through a comprehensive mo-
lecular evaluation of 295 primary gastric cancers. The proposed molecular classification divided 
gastric cancer into four subtypes: Epstein-Barr virus–positive, microsatellite unstable, genomic 
stable, and chromosomal instability. This information will be taken into account in future clinical 
trials and will be translated into clinical therapeutic decisions. To fully realize the clinical benefit, 
many challenges must be overcome. Rapid growth of high-throughput biology and functional 
validation of molecular targets will further deepen our knowledge of molecular dimensions of this 
cancer, allowing for personalized precision medicine.
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▒ REVIEW ▒
Gastric cancer (GC) is one of the most common and fatal dis-
eases, and nearly two-thirds of the cases are concentrated in East 
Asia.1 In Korea, GC is the second most common malignancy 
after thyroid cancer. It was ranked as the third cause of cancer 
mortality in 2012.2 An estimate of 35,000 people are expected 
to be newly diagnosed, and about 7,500 patients will die in 
2015.3 According to the National Cancer Screening Program 
that began in 1999, the proportion of early gastric cancer (EGC) 
has increased, and the prognosis of EGC is favorable even with-
out additional treatment after surgery.4,5 Radical D2 surgery with 
adjuvant chemotherapy has been established as a standard treat-
ment for locally advanced gastric cancer (AGC), and has im-
proved the prognosis of AGC.6-8 However, about half of patients 
with AGC experience recurrence, and the proportion of patients 
who benefit from adjuvant chemotherapy is around 20%,9-14 with 
cases of metastasis being the least amenable to treatment.15,16 
GC is a heterogeneous malignancy, which is the main reason 
for its different prognoses in patients with same clinical stage 
and for its diverse responses to the standard treatment. It is now 
widely appreciated that genomic complexity and heterogeneity 
are fundamental causes of tumor phenotypic characteristics de-
termining clinical outcomes. Therefore, understanding of the 
molecular and genetic characteristics is essential in effective and 
personalized management of GC. 
GC has been classified according to histo-morphologic fea-
tures. The World Health Organization (WHO) classifies GC into 
papillary, tubular, mucinous, and poorly cohesive carcinomas,17 
while the Lauren classification divides GC into intestinal, diffuse, 
and mixed types.18 However, these classification systems do not 
satisfactorily provide information relevant to clinical utilities 
and treatment guidelines. Over the past decades, the molecular 
landscape of GC has been shaped, and this review focuses on the 
molecular features of GC that can be translated into clinical use 
in order to guide precise therapeutic decisions. Details of surgi-
cal, adjuvant or peri-operative chemotherapy, and radiotherapy 
are beyond the scope of this review and readers would be direct-
ed to other reviews dealing with these issues.19 The recent The 
Cancer Genome Atlas (TCGA) study,20 a landmark study divid-
ing GC into four subtypes based on multi-dimensional profiling, 
(1) Epstein-Barr virus (EBV) tumor, (2) microsatellite unstable 
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(MSI) tumor, (3) genomically stable (GS) tumor, and (4) chro-
mosomal instability (CIN), is used as a roadmap for this review. 
We also provide the current status of recent and ongoing clini-
cal trials that focus on genomic alterations in molecular sub-
types for targeted therapeutics (summarized in Table 1).15,16,21-34
EPSTEIN-BARR VIRUS–POSITIVE  
GASTRIC CANCER
The incidence of EBV-positive GC has been reported to be 
around 10%20,35 and harbors a higher prevalence of DNA hy-
permethylation than other subtypes.20,36 The reason for extraor-
dinary DNA hypermethylation seems to be a cellular reaction to 
the viral infection.37 EBV-positive GC also has strong signatures 
of interleukin 12-mediated signaling events, which reflects high 
immune cell infiltration.20,38 Intriguingly, tumors of this subtype 
exhibit CD274 and PDCD1LG2 amplification of which pro-
teins PD-L1 and PD-L2, respectively, are related to immune sup-
pressive functions, particularly immune checkpoints. Further, 
amplification at the 9p24.1 locus containing JAK2, which en-
codes an oncogenic receptor tyrosine kinase (RTK), is also a po-
tential therapeutic target. Those findings seemed to support the 
rationale that this type of GC would be a relevant target of RTK 
and immune checkpoints inhibitors.20,37 A recent phase I study 
showed that pembrolizumab (MK-3475), one of the anti–PD-
1/2 immune checkpoint inhibitors, provided antitumor activity 
in patients with AGC that expressed PD-L1.21 Predilection of 
EBV-positive GC for PIK3CA mutation, which is related to the 
phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, has 
also been reported.20 Frequent PIK3CA mutations warrant evalu-
ation of PI3K inhibitors in EBV-positive GC. Although still in 
preclinical stages, BKM 120, which is a direct PIK3CA inhibi-
tor, and BEZ235, a dual PIK3CA and mammalian target of ra-
pamycin (mTOR) inhibitor, have been reported to reduce cell 
viability and induce apoptosis in GC cell lines.22 Additionally, 
the ARID1A mutation was detected in 10% of GC39 and was 
Table 1. Current status of targeted therapies based on molecular alterations according to GC subtype
Subtypes Molecular targets Alterations Suggested therapeutics Clinical trial
EBV positive GC PD-L1/2 Overexpression Pembrolizumab Phase I21
 
PIK3CA Mutation BKM120/BEZ235 Preclinical/Preclinical22
ARID1A Mutation NA NA
MSI GC MMR Deficiency Pembrolizumab Phase II23
GS GC CDH1 Mutation Prophylactic gastrectomy
 (germline mutation)24,a
-
RHOA Mutation NA NA
CLDN18-ARHGAP Fusion NA NA
CIN GC TP53 Mutation NA NA
SMAD4 Mutation NA NA
APC Mutation NA NA
EGFR Overexpression Cetuximab Phase III (EXPAND trial, negative)25
EGFR Overexpression Panitumumab Phase III (REAL-3 trial, negative)26
HER2 Overexpression Trastuzumab Phase III (ToGa trial, approved)16
HER2 Overexpression Trastuzumab Phase III (HELOISE trial, ongoing
NCT01450696)
HER2 Overexpression Pertuzumab Phase III (JACOB trial, ongoing
NCT01774786)
HER2 Overexpression Trastuzumab emtansine Phase II/III (GATSBY trial, ongoing
NCT01641939)
EGFR/HER2 Overexpression Lapatinib Phase III (TyTAN trial, negative)27
MET Overexpression Crizotinib/rilotumumab Phase I/Phase II (terminated)28-31,b
MET Overexpression Onartuzumab Phase III (METGASTRIC trial, ongoing
NCT01662869)
VEGF Overexpression Bevacizumab Phase III (AVAGAST trial, negative)15,32
VEGFR2 Overexpression Ramucirumab Phase III (REGARD33 & RAINBOW34 trials, 
  approved)
VEGFR2/TIE2 Overexpression Regorafenib Phase II (INTEGRATE trial, ongoing
ACTRN12612000239864)
GC, gastric cancer; EBV, Epstein-Barr virus; N/A, not available; MSI, microsatellites unstable; GS, genomically stable; CIN, chromosomal instability.
aMainly in the Western countries; bAmgen-sponsored clinical trials of rilotumumab in advanced gastric cancer were terminated based on the pre-planned 
safety review by independent data monitoring committee.
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found most frequently in EBV-positive GC.20 This mutation 
encodes a component of SWI/SNF complex and acts as a tumor 
suppressor in cancer.39 Recently, it was reported that EZH2 in-
hibitor could be a novel therapeutic targeting ARID1A-mutat-
ed cancers.40 Therefore, the ARID1A mutation provides another 
clinically actionable genetic alteration in EBV-positive GC that 
should be validated in a clinical study. Based on these findings, 
the molecular characteristics of EBV-positive GC are distinct 
from those of other GC subtypes, and some of the genetic alter-
ations can be therapeutically exploited. 
MICROSATELLITE UNSTABLE  
GASTRIC CANCER
MSI GC is related to the loss of function of mismatch repair 
(MMR) genes and is associated with older age, female gender, 
intestinal type, and less aggressive tumor stages.20,41,42 Because 
the function of the MMR mechanism is defective mainly due to 
MLH1 silencing by promoter hypermethylation,20 this subtype 
has more mutations per megabase (Mb) compared to other types 
of GC. Intriguingly, MSI tumors possess common alterations in 
major histocompatibility complex (MHC) class I-related genes, 
including HLA-B and B2M. Since these MHC class I genes 
function in proper antigen presentation to the host immune sys-
tem, these genomic alterations could provide hypermutated MSI 
GC with the selective advantage of immune surveillance evasion. 
The incidence of MSI GC was previously reported to be 8.5%–
37.8%.43 While the prognosis of MSI GC was not assessed in 
comparison with those of other molecular subtypes in a TCGA 
study,20 a meta-analysis43 and a recent study regarding the mo-
lecular classification of GC reported that MSI GC had the best 
overall prognosis with the lowest recurrence rate.44 Importantly, 
the prognosis of MSI GC was prominent in the population treat-
ed with surgery alone. Indeed, the prognosis of MSI GC with-
out chemotherapy was similar to that of patients who received 
chemotherapy after surgery,45 implying that the MSI subtype is 
unresponsive to chemotherapy in an adjuvant setting,41 like MSI 
colon cancer.46,47 Additionally, a recent phase II study that eval-
uated the clinical utility of pembrolizumab showed that MMR 
status predicted the benefit of pembrolizumab,23 and a higher 
mutational load was reported to be related to positive response 
to anti-CTLA-4 in melanoma48 and PD-1 antibody in non-small 
cell lung cancer.49 The legitimate explanation might be that 
immune infiltrate related with mutation was directed at neoan-
tigens, and recognition plays an important role in the antitu-
mor immune response.23 Consequently, MSI status is a promising 
biomarker to predict the prognosis and responses to immune 
checkpoint inhibitor as well as chemotherapy in GC, as in colon 
cancer.50 There is no consensus on the definition of GC-specific 
MSI in clinical settings at this time, and studies have used dif-
ferent criteria to define MSI.20,43,45,51,52 Thus, it is necessary to es-
tablish appropriate analysis standards for MSI status in GC for 
precise detection and translation of “MSI-ness” for clinical ther-
apeutic decisions. 
GENOMICALLY STABLE GASTRIC CANCER 
The GS subtype of GC is best represented as a diffuse type of 
GC, with lower mutation burden compared to other subtypes 
and occurring at a relatively early age.20 CDH1 mutation is one 
of the representative mutations in the GS subtype. CDH1 germ-
line mutations are known to be related to hereditary diffuse GC. 
When patients harbor pathogenic hotspot mutations in CDH1, 
prophylactic gastrectomy is recommended.24 However, only two 
CDH1 mutations, neither of which is a pathogenic hotspot mu-
tation, were identified in a recent TCGA study.20 Another study 
reported that somatic alterations of CDH1 were present in ap-
proximately 30% of GC cases, and structural alterations in CDH1 
were related to poor prognosis.53 In addition to CDH1 muta-
tions, GS subtype tumors have RHOA mutations and CLDN18-
ARHGAP 6 or 26 fusions.20,54,55 RHOA is known to modulate 
downstream Rho signaling, and its mutation imparts resistance 
to anoikis, a form of programmed cell death.54 Also, RHOA acts 
to control actin-myosin-dependent cell contractility and motil-
ity;56,57 thus, its mutation might contribute to dispersed growth 
and poorly cohesive patterns of diffuse type GC,20 which is associ-
ated with poor prognosis. Thus, the RHOA mutation could be a 
good candidate for new approaches targeting GS subtype GC.37 
CLDN18-ARHGAP6 or 26 fusions are mutually exclusive to 
RHOA and CDH1 mutation among GS tumors. The discovery 
of recurrent interchromosomal translocation between CLDN18 
and ARHGAP26 further implies biological significance of cell 
adhesion and deregulated Rho signaling in GS tumors since 
CLDN18 is involved in intercellular tight junction structure, and 
ARHGAP26, a GTPase-activating protein, imparts Rho sig-
naling activation by facilitating the conversion of Rho GTPases 
to the GDP state. A recent study reported that this type of fu-
sion in epithelial cells mediates epithelial disintegration and is 
related to epithelial-mesenchymal transition (EMT).58 There-
fore, the novel discoveries of RHOA mutation and CLDN18-
ARHGAP26 fusion could be exploited to develop new thera-
peutic strategies against GS subtype tumors,37 which are known 
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to harbor the poorest prognosis of all GC tumors.44 However, 
translating those new strategies to clinical practice is in the early 
stages and is largely lacking evidence of functional validity. Ad-
ditionally, there have been no clinical trials to assess the efficacy 
of targeting those genomic alterations in GS subtype tumors. 
CHROMOSOMAL INSTABILITY  
GASTRIC CANCER
CIN subtype GC is related to intestinal type histology, fre-
quent TP53 mutations, and amplification of RTKs.20 TP53 mu-
tation is the most frequently detected mutation in GC, occurring 
in up to 50% of all cases59 and 71% of cases of CIN subtype GC.20 
TP53 mutation is associated with high levels of somatic copy 
number variations in both chromosomal and focal gene regions.60 
Also, other canonical tumor suppressor genes such as SMAD4 
and APC have been reported to be mutated in GC.61 Since tumor 
suppressor genes are regarded as poor candidates for targeted 
therapy development, alterations in RTKs will be discussed in 
this review. 
 
EPIDERMAL GROWTH FACTOR RECEPTOR
The human epidermal growth factor receptors (HER) are a 
family of four transmembrane RTKs, ErbB1 (epidermal 
growth factor receptor, EGFR), ErbB2 (HER2), ErbB3 
(HER3), and ErbB4 (HER4),62 that regulate diverse down-
stream signaling pathways and play an important role in GC 
development and progression. A biomarker study from Adjuvant 
Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC),14 a 
phase III randomized controlled trial (RCT) that compared the 
effect of adjuvant S-1 over surgery alone in locally AGC, 
showed that EGFR overexpression was related to poor progno-
sis but was not found to be the case for HER2.63 There have 
been two RCTs that investigated the benefit of EGFR inhibition 
(EXPAND25 trial for cetuximab and REAL-3 trial26 for panitu-
mumab as first-line therapy); however, both trials failed to prove 
the additional clinical benefit of anti-EGFR antibody over stan-
dard chemotherapy. 
 
HER2
The success of a clinical trial that investigated the effects of 
trastuzumab targeting HER2 in HER2-overexpressed GC pa-
tients resulted in changes in clinical practice. Addition of trastu-
zumab to chemotherapy as the first-line treatment of metastatic 
GC improved overall survival.16 However, an updated survival 
analysis showed that the benefit of the trastuzumab decreased 
over time, the difference in median overall survival was reduced 
from 2.7 to 1.4 months, and the hazard ratio increased from 0.74 
in primary analysis to 0.80.64 This raises a concern, requiring 
further investigation to clarify the clinical benefit of trastuzum-
ab in HER2-overexpressing GC patients. Indeed, two first-line 
therapy trials are underway to investigate the effect of addition 
of pertuzumab to a standard HER2 targeting regimen and the 
effect of two dose levels of trastuzumab (JACOB and HELI-
OSE, respectively). 
The frequency of HER2 mutation was reported to be 5% 
(9/180) in GC, and the relationship between HER2 mutation 
and responsiveness to trastuzumab has not yet been determined. 
Another clinically important issue regarding HER2 mutation 
and amplification might be derived from a recent EGFR bio-
marker study in non-small cell lung cancer patients receiving 
gefitinib, where EGFR mutation and amplification correlated 
with prolonged progression-free survival.65 Based on this, it 
might be worthwhile to investigate the clinical benefit of HER2 
inhibitor in HER2-mutated and amplified GC as alternative 
candidates for HER2-targeted therapy.66 A phase III trial (TY-
TAN) was conducted to investigate the benefit of lapatinib, a 
dual inhibitor of EGFR and HER2, as a second-line therapy for 
AGC. Although overall survival was not significantly different, 
post hoc analysis demonstrated that the HER2 immunohisto-
chemistry 3+ subgroup showed statistically significant prolon-
gation of overall survvial.27 
KRAS
KRAS is one of the members of the RAS family, and its muta-
tion plays an important role in tumorigenesis by activating down-
stream pathways such as PI3K and RAF. The frequency of KRAS 
mutations in GC was reported as 1.5%–5.8%, and most of 
them were transversions.67 Overexpression of wild-type KRAS 
seemed to be related to acquired resistance to inhibitors of other 
tyrosine kinase in GC cells.68 A phase II trial that evaluated the 
efficacy of selumetinib, an inhibitor of MEK1/MEK2, down-
stream of KRAS, for KRAS-mutant non-small cell lung cancer 
demonstrated promising efficacy and thereby warrants further 
clinical investigation.69 Thus, a MEK inhibitor could be a poten-
tial therapeutic agent for targeting KRAS-mutated GC; howev-
er, evidence from a clinical trial is required. 
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 MESENCHYMAL EPITHELIAL TRANSITION 
FACTOR
Mesenchymal epithelial transition factor (MET) amplifica-
tion was not common (2%, 10/489) in GC it was reported to 
be related with poor prognosis.28 However, two studies have re-
ported the possibility of targeted therapy for MET-positive GC. 
An expanded phase I cohort study showed that patients with 
MET amplification had a favorable response to crizotinib (PF-
02341066), a MET/anaplastic lymphoma kinase tyrosine kinase 
inhibitor.28 Furthermore, rilotumumab (AMG 102), a fully hu-
manized monoclonal antibody against hepatocyte growth fac-
tor/MET, demonstrated favorable overall survival especially for 
patients with MET-positive GC.29 Based on those results, subse-
quent trials were conducted (RILOMET-130 and NCT02137343); 
however, all Amgen-sponsored clinical trials of rilotumumab in 
AGC were terminated based on a pre-planned safety review by 
the data monitoring committee due to an increase in death with 
the study drug.31 Currently, a small-molecule MET inhibitor is 
under investigation for MET-amplified GC. 
 
BRAF
BRAF mutations are related to tumorigenesis, and dysregu-
lated BRAF activity instigates abnormal cell growth and prolif-
eration through MEK and ERK pathways.70 The specific muta-
tion BRAFV600E is the most common type of BRAF mutation in 
melanoma, and vemurafenib, a BRAF inhibitor, was found to 
be beneficial in patients with BRAFV600E-mutated melanoma.71 
BRAF mutations are rarely observed in GC, with only 2.2% 
(7/319) of patients demonstrating BRAF mutation, most (five of 
seven BRAF mutations) of which were BRAFV599M;72 in addi-
tion, there were no BRAF mutations among 167 patients in the 
REAL-3 trial.26 Furthermore, only 0.2% of patients (1/508) with 
GC had a BRAFV600E mutation in another study.67 Therefore, it 
is not yet clear if BRAF mutation is a driver mutation in GC. 
VASCULAR ENDOTHELIAL GROWTH FACTOR 
RECEPTOR
Vascular endothelial growth factor receptor (VEGFR) expres-
sion is closely related to angiogenesis in tumorigenesis. Since an-
giogenesis is critical for tumor growth and metastasis, it is a 
therapeutic target for many cancer types. Bevacizumab, a 
monoclonal antibody that inhibits VEGF (VEGF-A), showed 
survival benefits in advanced colorectal cancer73 and non-small 
cell lung cancer.74 Also, a phase II trial that showed efficacy of 
bevacizumab for advanced gastro-esophageal cancer seemed to 
reinforce the success of targeted therapy against the VEGF 
pathway in gastric cancer.75 Despite initial enthusiasm regard-
ing its use, bevacizumab combined with chemotherapy as a first-
line therapy did not improve the overall survival of patients with 
GC in the AVAGAST trial. However, the more recent RAIN-
BOW34 and REGARD33 trials, which evaluated benefits of 
ramucirumab (antibody targeting VEGFR2) as second-line and 
first-line therapies, respectively, reported improved overall sur-
vival in GC patients. Intriguingly, subgroup analyses of the trials 
showed that benefit from VEGF-targeted therapy was observed 
mainly in non-Asian patients. Also, a subsequent biomarker 
study of AVAGAST showed that plasma VEGF-A and neuropi-
lin-1 levels could be prognostic and predictive of bevacizumab 
treatment in a non-Asian population.32 Those findings imply that 
GC is a complex and heterogeneous disease across the globe, 
which affects the response to anti-angiogenesis treatment and po-
tentially other target therapies.37,76 
CANCER STEM CELL-RELATED PATHWAYS 
Cancer stem cells that initiate tumorigenesis through self-re-
newal and differentiation are emerging concepts in cancer re-
search. Such cells activate EMT, oncogenic pathways, and em-
bryogenic pathways.77,78 Also, these cells are known to be resistant 
to chemotherapy and radiotherapy, while Wnt, Notch, and 
Hedgehog pathways are crucial to the maintenance of cancer 
stem cells. Transcriptional factors such as Snail, Slug, Twist, and 
Zeb1/2 coordinate the EMT, while transforming growth factor 
β (TGF-β) is a central signaling pathway related to transforma-
tion into EMT.79,80 TGF-β can act as a proto-oncogene, driving 
matrix deposit, stimulating EMT and stem cell renewal, and in-
hibiting apoptosis through transactivation of EGFR.81,82 Also, 
its downstream signaling pathway, PI3K/Akt/mTOR, aids in 
cancer stem cell maintenance.83 Thus, targeting this pathway with 
appropriate agents such as metformin would inhibit cellular 
transformation and selectively kill cancer stem cells, as previously 
demonstrated in breast cancer.84 Also, a recent report showed 
that patients with GC treated with metformin for diabetes mel-
litus had better survival compared to those treated with diabet-
ic medications other than metformin.85 GC stem cells express 
CD133, CD44, aldehyde dehydrogenase 1 (ALDH1), and ATP-
binding cassette sub-family G member 2 (ABCG2). CD44 and 
ALDH1 have been reported to be related to resistance to chemo-
therapy and radiotherapy.86 Amplification of the gene that en-
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codes the GC stem cell marker CD44 was observed in a TCGA 
study,20 suggesting the potential of exploiting genomic alteration 
in future development of cancer stem cell-directed therapies. 
CONCLUSIONS AND FUTURE PERSPECTIVES
Through extraordinary efforts over the past decades, our kn-
owledge on GC has advanced considerably, and standardized 
multidisciplinary treatment has improved the prognosis of GC. 
However, clinical development of targeted therapy in GC re-
mains inferior to those of other cancer types such as lung, breast, 
and colon cancer in terms of genetic sequencing and molecular 
therapeutics.87 Most of the targeted therapies have been investi-
gated without patient selection based on a biomarker, and the 
results have been disappointing, with only a few targeted ag-
ents16,33,34 showing benefit to patient survival at one year even af-
ter treatment for metastasis or recurrent GC. In the upcoming 
years, accumulation of genomic information and knowledge about 
molecular pathogenesis of GC will be accelerated through high-
throughput systems biology, and the treatment will be focused 
on targeting specific GC subtypes based on specific molecular 
characteristics (e.g., somatic driver alterations and amplifica-
tion). Presently, one of the hurdles in this achievement is the in-
tegration of knowledge from various disciplines and its transla-
tion into daily clinical practice. To achieve a sensible reduction 
in mortality due to this deadly disease, transdisciplinary cooper-
ation among clinicians, pathologists, bioiformaticians, compu-
tational biologists, and genomicists is required. 
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